AZD1981
Phase 2Small molecule
AstraZenecaAZD1981 is one of 69 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 2.
3
Indications
14
Total Trials
0
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
Xolair
RochePreclinical
Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Cinqair
TevaPreclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Asmanex
NovartisPreclinical
AZD1981
AstraZenecaPhase 2
Celexa
AbbViePreclinical
Spiriva
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Interaction3 trials
Asthma2 trials
Chronic Idiopathic Urticaria1 trial
4 more indications
Metabolism1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AZD1981. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company